Our recent collection of thought leadership features scientific publications from Precision authors Kathy Lang, Ross Maclean, Jason Shafrin, Meena Venkatachalam, and more!


COVID-19 Pandemic Vindicates the ISPOR Value Flower

What is the right price for a new treatment for COVID-19 and why the “value flower” model can more accurately value treatments which have a transformational impact on the lives of not only of patients, but also caregivers, employers, and broader society.


Creating Incentives To Narrow The Gap In Health Outcomes: Expanding Value Assessment To Incorporate Health Inequality. 

According to the Centers for Disease Control and Prevention (CDC), while African Americans represented 13 percent of the US population, as of May 30, 22 percent of COVID-19 patients were black. Furthermore, as of March 30, 33 percent of hospitalized COVID-19 patients were African American. These health disparities were well known before the COVID-19 pandemic; life expectancy for African Americans in the US is 3.5 years lower than for the American population as a whole. Although there is a universal acknowledgement that health inequalities need to be addressed, the question is “How?”